CD19 and acute lymphoblastic leukemia: Building on this concept, obecabtagene autoleucel (obe-cel), an autologous 4-1BB-based anti-CD19 CAR T-cell therapy incorporating a fast off-rate scFv with intermediate affinity, was evaluated in the phase Ib/II FELIX trial in adults with R/R B-ALL.